Cargando…

Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver

Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation...

Descripción completa

Detalles Bibliográficos
Autores principales: Feriod, Colleen N., Gustavo Oliveira, Andre, Guerra, Mateus T., Nguyen, Lily, Mitchell Richards, Kisha, Jurczak, Michael J., Ruan, Hai‐Bin, Paulo Camporez, Joao, Yang, Xiaoyong, Shulman, Gerald I., Bennett, Anton M., Nathanson, Michael H., Ehrlich, Barbara E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613674/
https://www.ncbi.nlm.nih.gov/pubmed/28966992
http://dx.doi.org/10.1002/hep4.1012
_version_ 1783266305605894144
author Feriod, Colleen N.
Gustavo Oliveira, Andre
Guerra, Mateus T.
Nguyen, Lily
Mitchell Richards, Kisha
Jurczak, Michael J.
Ruan, Hai‐Bin
Paulo Camporez, Joao
Yang, Xiaoyong
Shulman, Gerald I.
Bennett, Anton M.
Nathanson, Michael H.
Ehrlich, Barbara E.
author_facet Feriod, Colleen N.
Gustavo Oliveira, Andre
Guerra, Mateus T.
Nguyen, Lily
Mitchell Richards, Kisha
Jurczak, Michael J.
Ruan, Hai‐Bin
Paulo Camporez, Joao
Yang, Xiaoyong
Shulman, Gerald I.
Bennett, Anton M.
Nathanson, Michael H.
Ehrlich, Barbara E.
author_sort Feriod, Colleen N.
collection PubMed
description Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation. Here we show that the type 1 isoform of the inositol 1,4,5‐trisphosphate receptor (InsP(3)R1) specifically links ER calcium release to mitochondrial calcium signaling and lipid droplet formation in hepatocytes. Moreover, liver‐specific InsP(3)R1 knockout mice have impaired mitochondrial calcium signaling, decreased hepatic triglycerides, and reduced lipid droplet formation and are resistant to the development of fatty liver. Patients with nonalcoholic steatohepatitis, the most malignant form of fatty liver, have increased hepatic expression of InsP(3)R1, and the extent of ER–mitochondrial colocalization correlates with the degree of steatosis in human liver biopsies. Conclusion: InsP(3)R1 plays a central role in lipid droplet formation in hepatocytes, and the data suggest that it is involved in the development of human fatty liver disease. (Hepatology Communications 2017;1:23–35)
format Online
Article
Text
id pubmed-5613674
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56136742018-02-01 Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver Feriod, Colleen N. Gustavo Oliveira, Andre Guerra, Mateus T. Nguyen, Lily Mitchell Richards, Kisha Jurczak, Michael J. Ruan, Hai‐Bin Paulo Camporez, Joao Yang, Xiaoyong Shulman, Gerald I. Bennett, Anton M. Nathanson, Michael H. Ehrlich, Barbara E. Hepatol Commun Original Articles Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation. Here we show that the type 1 isoform of the inositol 1,4,5‐trisphosphate receptor (InsP(3)R1) specifically links ER calcium release to mitochondrial calcium signaling and lipid droplet formation in hepatocytes. Moreover, liver‐specific InsP(3)R1 knockout mice have impaired mitochondrial calcium signaling, decreased hepatic triglycerides, and reduced lipid droplet formation and are resistant to the development of fatty liver. Patients with nonalcoholic steatohepatitis, the most malignant form of fatty liver, have increased hepatic expression of InsP(3)R1, and the extent of ER–mitochondrial colocalization correlates with the degree of steatosis in human liver biopsies. Conclusion: InsP(3)R1 plays a central role in lipid droplet formation in hepatocytes, and the data suggest that it is involved in the development of human fatty liver disease. (Hepatology Communications 2017;1:23–35) John Wiley and Sons Inc. 2016-11-11 /pmc/articles/PMC5613674/ /pubmed/28966992 http://dx.doi.org/10.1002/hep4.1012 Text en © 2016 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Feriod, Colleen N.
Gustavo Oliveira, Andre
Guerra, Mateus T.
Nguyen, Lily
Mitchell Richards, Kisha
Jurczak, Michael J.
Ruan, Hai‐Bin
Paulo Camporez, Joao
Yang, Xiaoyong
Shulman, Gerald I.
Bennett, Anton M.
Nathanson, Michael H.
Ehrlich, Barbara E.
Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
title Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
title_full Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
title_fullStr Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
title_full_unstemmed Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
title_short Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
title_sort hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613674/
https://www.ncbi.nlm.nih.gov/pubmed/28966992
http://dx.doi.org/10.1002/hep4.1012
work_keys_str_mv AT feriodcolleenn hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT gustavooliveiraandre hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT guerramateust hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT nguyenlily hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT mitchellrichardskisha hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT jurczakmichaelj hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT ruanhaibin hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT paulocamporezjoao hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT yangxiaoyong hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT shulmangeraldi hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT bennettantonm hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT nathansonmichaelh hepaticinositol145trisphosphatereceptortype1mediatesfattyliver
AT ehrlichbarbarae hepaticinositol145trisphosphatereceptortype1mediatesfattyliver